VEGFA and nonpapillary renal cell carcinoma: Subsequently, the LITESPARK-005 phase III trial was conducted comparing belzutifan to everolimus in 746 sporadic unresectable or metastatic ccRCC patients who had disease progression after treatment with an immune checkpoint inhibitor and a VEGF inhibitor (received in sequence or combination) [9].